Shares of Agenus (NASDAQ: AGEN) are up 3.7% this morning after the company launched a new subsidiary company, AgenTus Therapeutics, Inc., for its cell therapy business. AgenTus will focus on the discovery, development, and commercialization of breakthrough immuno-oncology (I-O) “living drugs” to advance potential cures for cancer patients. Bruno Lucidi has been appointed as CEO of the AgenTus subsidiary. “AgenTus will operate with remarkable science, innovation, and access to Agenus capabilities and expertise, all giving the subsidiary competitive advantage through the delivery of innovative living drugs to cancer patients looking for cures,” Agenus chairman and CEO Garo Armen, Ph.D. stated in the news release.
To view the full press release, visit http://nnw.fm/w8bpE
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
